{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T03:46:33Z","timestamp":1785815193753,"version":"3.56.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T00:00:00Z","timestamp":1656460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,10,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ductal carcinoma in situ (DCIS) is treated to prevent subsequent ipsilateral invasive breast cancer (iIBC). However, many DCIS lesions will never become invasive. To prevent overtreatment, we need to distinguish harmless from potentially hazardous DCIS. We investigated whether the immune microenvironment (IME) in DCIS correlates with transition to iIBC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients were derived from a Dutch population-based cohort of 10,090 women with pure DCIS with a median follow-up time of 12 years. Density, composition and proximity to the closest DCIS cell of CD20<jats:sup>+<\/jats:sup> B-cells, CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>+<\/jats:sup> T-cells, CD3<jats:sup>+<\/jats:sup>CD8<jats:sup>\u2212<\/jats:sup> T-cells, CD3<jats:sup>+<\/jats:sup>FOXP3<jats:sup>+<\/jats:sup> regulatory T-cells, CD68<jats:sup>+<\/jats:sup> cells, and CD8<jats:sup>+<\/jats:sup>Ki67<jats:sup>+<\/jats:sup> T-cells was assessed with multiplex immunofluorescence (mIF) with digital whole-slide analysis and compared between primary DCIS lesions of 77 women with subsequent iIBC (cases) and 64 without (controls).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Higher stromal density of analysed immune cell subsets was significantly associated with higher grade, ER negativity, HER-2 positivity, Ki67\u2009\u2265\u200914%, periductal fibrosis and comedonecrosis (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Density, composition and proximity to the closest DCIS cell of all analysed immune cell subsets did not differ between cases and controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>IME features analysed by mIF in 141 patients from a well-annotated cohort of pure DCIS with long-term follow-up are no predictors of subsequent iIBC, but do correlate with other factors (grade, ER, HER2 status, Ki-67) known to be associated with invasive recurrences.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-01888-2","type":"journal-article","created":{"date-parts":[[2022,6,29]],"date-time":"2022-06-29T16:02:56Z","timestamp":1656518576000},"page":"1201-1213","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk"],"prefix":"10.1038","volume":"127","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1554-2887","authenticated-orcid":false,"given":"Mathilde M.","family":"Almekinders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4767","authenticated-orcid":false,"given":"Tycho","family":"Bismeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2825-3387","authenticated-orcid":false,"given":"Tapsi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1562-2649","authenticated-orcid":false,"given":"Bram","family":"Thijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Vonk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-1636","authenticated-orcid":false,"given":"Edwin R.","family":"Parra Cuentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio I.","family":"Wistuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7856-1981","authenticated-orcid":false,"given":"Lindy L.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris M.","family":"Seignette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Hofland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0551-7813","authenticated-orcid":false,"given":"Joyce","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annegien","family":"Broeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3020-5790","authenticated-orcid":false,"given":"Brian","family":"Menegaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewyk","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin E.","family":"de Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hooijberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3488-4935","authenticated-orcid":false,"given":"Esther","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8663-2671","authenticated-orcid":false,"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8940-2676","authenticated-orcid":false,"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Grand Challenge PRECISION Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Lips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelle","family":"Wesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewyk","family":"Wessels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Futreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,29]]},"reference":[{"key":"1888_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/jnci\/94.20.1546","volume":"94","author":"VL Ernster","year":"2002","unstructured":"Ernster VL, Ballard-Barbash R, Barlow WE, Zheng Y, Weaver DL, Cutter G, et al. Detection of ductal carcinoma in situ in women undergoing screening mammography. J Natl Cancer Inst. 2002;94:1546\u201354. https:\/\/doi.org\/10.1093\/jnci\/94.20.1546","journal-title":"J Natl Cancer Inst"},{"key":"1888_CR2","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/jnci\/djq101","volume":"102","author":"K Kerlikowske","year":"2010","unstructured":"Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2010;102:627\u201337. https:\/\/doi.org\/10.1093\/jnci\/djq101","journal-title":"J Natl Cancer Inst"},{"key":"1888_CR3","unstructured":"UK, C. R. Breast carcinoma in situ (1993\u20132017). https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/breast-cancer\/incidence-in-situ#heading-Zero (2017, Accessed 22 Mar 2021)."},{"key":"1888_CR4","unstructured":"(IKNL), N. C. C. O. DCIS incidence trends over time. https:\/\/www.iknl.nl\/nieuws\/2018\/borstkanker-in-nederland-trends-over-de-periode-19. Utrecht, The Netherlands: Netherlands Comprehensive Cancer Organization; 2018."},{"key":"1888_CR5","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1097\/SLA.0000000000002239","volume":"267","author":"LE Elshof","year":"2018","unstructured":"Elshof LE, Schmidt MK, Rutgers EJT, van Leeuwen FE, Wesseling J, Schaapveld M. Cause-specific mortality in a population-based cohort of 9799 women treated for ductal carcinoma in situ. Ann Surg. 2018;267:952\u20138. https:\/\/doi.org\/10.1097\/SLA.0000000000002239","journal-title":"Ann Surg"},{"key":"1888_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1904-7","volume":"15","author":"KE Stuart","year":"2015","unstructured":"Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. 2015;15:890 https:\/\/doi.org\/10.1186\/s12885-015-1904-7","journal-title":"BMC Cancer"},{"key":"1888_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-016-3973-y","volume":"159","author":"LE Elshof","year":"2016","unstructured":"Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Res Treat. 2016;159:553\u201363. https:\/\/doi.org\/10.1007\/s10549-016-3973-y","journal-title":"Breast Cancer Res Treat"},{"key":"1888_CR8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/jnci\/djy220","volume":"111","author":"MD Ryser","year":"2019","unstructured":"Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, et al. Cancer Outcomes in DCIS patients without locoregional treatment. J Natl Cancer Inst. 2019;111:952\u201360. https:\/\/doi.org\/10.1093\/jnci\/djy220","journal-title":"J Natl Cancer Inst"},{"key":"1888_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/sj.bjc.6605718","volume":"103","author":"SE Pinder","year":"2010","unstructured":"Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, et al. A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR\/ANZ DCIS trial. Br J Cancer. 2010;103:94\u2013100. https:\/\/doi.org\/10.1038\/sj.bjc.6605718","journal-title":"Br J Cancer"},{"key":"1888_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/annonc\/mdw623","volume":"28","author":"G Pruneri","year":"2017","unstructured":"Pruneri G, Lazzeroni M, Bagnardi V, Tiburzio GB, Rotmensz N, DeCensi A, et al. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. Ann Oncol. 2017;28:321\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdw623","journal-title":"Ann Oncol"},{"key":"1888_CR11","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/his.14055","volume":"76","author":"AA Thike","year":"2020","unstructured":"Thike AA, Chen X, Koh VCY, Binte Md Nasir ND, Yeong JPS, Bay BH, et al. Higher densities of tumour-infiltrating lymphocytes and CD4(\u2009+\u2009) T cells predict recurrence and progression of ductal carcinoma in situ of the breast. Histopathology. 2020;76:852\u201364. https:\/\/doi.org\/10.1111\/his.14055","journal-title":"Histopathology"},{"key":"1888_CR12","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1245\/s10434-019-07562-x","volume":"26","author":"F Darvishian","year":"2019","unstructured":"Darvishian F, Ozerdem U, Adams S, Chun J, Pirraglia E, Kaplowitz E, et al. Tumor-infiltrating lymphocytes in a contemporary cohort of women with ductal carcinoma in situ (DCIS). Ann Surg Oncol. 2019;26:3337\u201343. https:\/\/doi.org\/10.1245\/s10434-019-07562-x","journal-title":"Ann Surg Oncol"},{"key":"1888_CR13","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3389\/fonc.2020.01486","volume":"10","author":"A Farolfi","year":"2020","unstructured":"Farolfi A, Petracci E, Serra L, Ravaioli A, Bravaccini S, Ravaioli S, et al. Tumor-infiltrating lymphocytes (TILs) and risk of a second breast event after a ductal carcinoma in situ. Front Oncol. 2020;10:1486 https:\/\/doi.org\/10.3389\/fonc.2020.01486","journal-title":"Front Oncol"},{"key":"1888_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01267-w","volume":"22","author":"M Kim","year":"2020","unstructured":"Kim M, Chung YR, Kim HJ, Woo JW, Ahn S, Park SY. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22:32 https:\/\/doi.org\/10.1186\/s13058-020-01267-w","journal-title":"Breast Cancer Res"},{"key":"1888_CR15","doi-asserted-by":"publisher","unstructured":"Agahozo MC, van Bockstal MR, Groenendijk FH, van den Bosch TPP, Westenend PJ, van Deurzen CHM. Ductal carcinoma in situ of the breast: immune cell composition according to subtype. Modern Pathol. https:\/\/doi.org\/10.1038\/s41379-019-0331-8 (2019).","DOI":"10.1038\/s41379-019-0331-8"},{"key":"1888_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10549-016-4036-0","volume":"161","author":"MJ Campbell","year":"2017","unstructured":"Campbell MJ, Baehner F, O\u2019Meara T, Ojukwu E, Han B, Mukhtar R, et al. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2017;161:17\u201328. https:\/\/doi.org\/10.1007\/s10549-016-4036-0","journal-title":"Breast Cancer Res Treat"},{"key":"1888_CR17","doi-asserted-by":"publisher","unstructured":"Chen XY, Thike AA, Md Nasir ND, Koh VCY, Bay BH, Tan PH. Higher density of stromal M2 macrophages in breast ductal carcinoma in situ predicts recurrence. Virchows Arch, https:\/\/doi.org\/10.1007\/s00428-019-02735-1 (2020).","DOI":"10.1007\/s00428-019-02735-1"},{"key":"1888_CR18","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1038\/s41379-018-0040-8","volume":"31","author":"MS Toss","year":"2018","unstructured":"Toss MS, Miligy I, Al-Kawaz A, Alsleem M, Khout H, Rida PC, et al. Prognostic significance of tumor-infiltrating lymphocytes in ductal carcinoma in situ of the breast. Mod Pathol. 2018;31:1226\u201336. https:\/\/doi.org\/10.1038\/s41379-018-0040-8","journal-title":"Mod Pathol"},{"key":"1888_CR19","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2159-8290.CD-17-0222","volume":"7","author":"CR Gil Del Alcazar","year":"2017","unstructured":"Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017;7:1098\u2013115. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0222","journal-title":"Cancer Discov"},{"key":"1888_CR20","doi-asserted-by":"publisher","unstructured":"Visser LL, Elshof LE, Schaapveld M, Van de Vijver K, Groen EJ, Almekinders MM, et al. Clinicopathological risk factors for an invasive breast cancer recurrence after ductal carcinoma in situ-a nested case-control study. Clin Cancer Res. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0201 (2018).","DOI":"10.1158\/1078-0432.CCR-18-0201"},{"key":"1888_CR21","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1038\/bjc.2013.147","volume":"108","author":"M Lazzeroni","year":"2013","unstructured":"Lazzeroni M, Guerrieri-Gonzaga A, Botteri E, Leonardi MC, Rotmensz N, Serrano D, et al. Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. Br J Cancer. 2013;108:1593\u2013601. https:\/\/doi.org\/10.1038\/bjc.2013.147","journal-title":"Br J Cancer"},{"key":"1888_CR22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/jnci\/djp082","volume":"101","author":"MC Cheang","year":"2009","unstructured":"Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736\u201350. https:\/\/doi.org\/10.1093\/jnci\/djp082","journal-title":"J Natl Cancer Inst"},{"key":"1888_CR23","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Sautes-Fridman","year":"2019","unstructured":"Sautes-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307\u201325. https:\/\/doi.org\/10.1038\/s41568-019-0144-6","journal-title":"Nat Rev Cancer"},{"key":"1888_CR24","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.semcancer.2017.10.003","volume":"52","author":"MV Dieci","year":"2018","unstructured":"Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, et al. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018;52:16\u201325. https:\/\/doi.org\/10.1016\/j.semcancer.2017.10.003","journal-title":"Semin Cancer Biol"},{"key":"1888_CR25","doi-asserted-by":"publisher","unstructured":"Chen XY, Thike AA, Koh VCY, Nasir NDM, Bay BH, Tan PH. Breast ductal Carcinoma in situ associated with microinvasion induces immunological response and predicts ipsilateral invasive recurrence. Virchows Arch. https:\/\/doi.org\/10.1007\/s00428-020-02959-6 (2020).","DOI":"10.1007\/s00428-020-02959-6"},{"key":"1888_CR26","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1158\/1078-0432.CCR-17-0743","volume":"23","author":"S Hendry","year":"2017","unstructured":"Hendry S, Pang JB, Byrne DJ, Lakhani SR, Cummings MC, Campbell IG, et al. Relationship of the breast ductal carcinoma in situ immune microenvironment with clinicopathological and genetic features. Clin Cancer Res. 2017;23:5210\u20137. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0743","journal-title":"Clin Cancer Res"},{"key":"1888_CR27","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1038\/s41416-020-0797-7","volume":"122","author":"MS Toss","year":"2020","unstructured":"Toss MS, Abidi A, Lesche D, Joseph C, Mahale S, Saunders H, et al. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ. Br J Cancer. 2020;122:1496\u2013506. https:\/\/doi.org\/10.1038\/s41416-020-0797-7","journal-title":"Br J Cancer"},{"key":"1888_CR28","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/his.13217","volume":"71","author":"I Miligy","year":"2017","unstructured":"Miligy I, Mohan P, Gaber A, Aleskandarany MA, Nolan CC, Diez-Rodriguez M, et al. Prognostic significance of tumour infiltrating B lymphocytes in breast ductal carcinoma in situ. Histopathology. 2017;71:258\u201368. https:\/\/doi.org\/10.1111\/his.13217","journal-title":"Histopathology"},{"key":"1888_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00205-5","volume":"7","author":"PL Narayanan","year":"2021","unstructured":"Narayanan PL, Raza SEA, Hall AH, Marks JR, King L, West RB, et al. Unmasking the immune microecology of ductal carcinoma in situ with deep learning. NPJ Breast Cancer. 2021;7:19 https:\/\/doi.org\/10.1038\/s41523-020-00205-5","journal-title":"NPJ Breast Cancer"},{"key":"1888_CR30","doi-asserted-by":"publisher","first-page":"e1218106","DOI":"10.1080\/2162402X.2016.1218106","volume":"5","author":"M Semeraro","year":"2016","unstructured":"Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, et al. The ratio of CD8(\u2009+\u2009)\/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ. Oncoimmunology. 2016;5:e1218106 https:\/\/doi.org\/10.1080\/2162402X.2016.1218106","journal-title":"Oncoimmunology"},{"key":"1888_CR31","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1001\/jamaoncol.2015.2510","volume":"1","author":"SA Narod","year":"2015","unstructured":"Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1:888\u201396. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2510","journal-title":"JAMA Oncol"},{"key":"1888_CR32","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/cam4.715","volume":"5","author":"M Morita","year":"2016","unstructured":"Morita M, Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Kanomata N, et al. CD8(\u2009+\u2009) tumor-infiltrating lymphocytes contribute to spontaneous \u201chealing\u201d in HER2-positive ductal carcinoma in situ. Cancer Med. 2016;5:1607\u201318. https:\/\/doi.org\/10.1002\/cam4.715","journal-title":"Cancer Med"},{"key":"1888_CR33","doi-asserted-by":"publisher","unstructured":"Greenwald NF, Miller G, Moen E, Kong A, Kagel A, Fullaway CC, et al. Whole-cell segmentation of tissue images with human-level performance using large-scale data annotation and deep learning. Nat Biotechnol. https:\/\/doi.org\/10.1101\/2021.03.01.431313 (2021).","DOI":"10.1101\/2021.03.01.431313"},{"key":"1888_CR34","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2018.07.010","volume":"174","author":"Y Goltsev","year":"2018","unstructured":"Goltsev Y, Samusik N, Kennedy-Darling J, Bhate S, Hale M, Vazquez G, et al. Deep profiling of mouse splenic architecture with CODEX multiplexed imaging. Cell. 2018;174:968\u201381.e915 https:\/\/doi.org\/10.1016\/j.cell.2018.07.010.","journal-title":"Cell"},{"key":"1888_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21615-4","volume":"12","author":"L Brady","year":"2021","unstructured":"Brady L, Kriner M, Coleman I, Morrissey C, Roudier M, True LD, et al. Inter- and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling. Nat Commun. 2021;12:1426 https:\/\/doi.org\/10.1038\/s41467-021-21615-4","journal-title":"Nat Commun"},{"key":"1888_CR36","doi-asserted-by":"publisher","first-page":"eaax5851","DOI":"10.1126\/sciadv.aax5851","volume":"5","author":"L Keren","year":"2019","unstructured":"Keren L, Bosse M, Thompson S, Risom T, Vijayaragavan K, McCaffrey E, et al. MIBI-TOF: a multiplexed imaging platform relates cellular phenotypes and tissue structure. Sci Adv. 2019;5:eaax5851. https:\/\/doi.org\/10.1126\/sciadv.aax5851","journal-title":"Sci Adv"},{"key":"1888_CR37","doi-asserted-by":"publisher","unstructured":"Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nat Genet. 2022;54:850\u201360. https:\/\/doi.org\/10.1038\/s41588-022-01082-3","DOI":"10.1038\/s41588-022-01082-3"},{"key":"1888_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00232-w","volume":"7","author":"MMM Almekinders","year":"2021","unstructured":"Almekinders MMM, Schaapveld M, Thijssen B, Visser LL, Bismeijer T, Sanders J, et al. Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. NPJ Breast Cancer. 2021;7:31 https:\/\/doi.org\/10.1038\/s41523-021-00232-w","journal-title":"NPJ Breast Cancer"},{"key":"1888_CR39","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","volume":"51","author":"A Francis","year":"2015","unstructured":"Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer. 2015;51:2296\u2013303. https:\/\/doi.org\/10.1016\/j.ejca.2015.07.017","journal-title":"Eur J Cancer"},{"key":"1888_CR40","doi-asserted-by":"publisher","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","volume":"9","author":"ES Hwang","year":"2019","unstructured":"Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9:e026797 https:\/\/doi.org\/10.1136\/bmjopen-2018-026797","journal-title":"BMJ Open"},{"key":"1888_CR41","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","volume":"51","author":"LE Elshof","year":"2015","unstructured":"Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer. 2015;51:1497\u2013510. https:\/\/doi.org\/10.1016\/j.ejca.2015.05.008","journal-title":"Eur J Cancer"},{"key":"1888_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2017.12.007","volume":"172","author":"AK Casasent","year":"2018","unstructured":"Casasent AK, Schalck A, Gao R, Sei E, Long A, Pangburn W, et al. Multiclonal invasion in breast tumors identified by topographic single cell sequencing. Cell. 2018;172:205\u201317.e212 https:\/\/doi.org\/10.1016\/j.cell.2017.12.007.","journal-title":"Cell"},{"key":"1888_CR43","unstructured":"Federa-COREON. Dutch regulations and the Code of Conduct. Rotterdam, The Netherlands: Federa-COREON. https:\/\/www.coreon.org\/. Accession date 27 June 2022."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01888-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01888-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01888-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T12:04:51Z","timestamp":1664366691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01888-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,29]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10,19]]}},"alternative-id":["1888"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01888-2","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,29]]},"assertion":[{"value":"23 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the review boards of the Netherlands Cancer Registry (NKR request K12.281; January 3, 2013) the Dutch National Pathology Automated Archive (PALGA, LZV990; April 16, 2013) and the locoregional institutional review board within the Netherlands Cancer Institute. The secondary use of tissue and data in this study are covered by an opt-out regimen conform Dutch regulations, the Codes of Conduct of Federa-COREON [] and the international Guideline on Good Clinical Practice. The study also meets the General Data Protection Regulation (GDPR) criteria that came into effect on 25 May 2018.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}